Recombinant AAV Capsid Variants for Tissue-Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adeno-associated viral vectors face limitations in delivery efficiency and tissue tropism, undermining their therapeutic efficacy in gene therapy applications.
Innovation Solution
Development of recombinant AAV vectors with novel capsid proteins to enhance delivery efficiency and tissue specificity, utilizing a capsid library construction strategy to improve transduction efficiency in various tissues and cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional AAV vectors are used for gene delivery, then the vector structure is simple and manufacturing is easier, but delivery efficiency and tissue tropism are limited
Solution Approach 1:
The patent modifies the capsid protein parameters of AAV vectors by introducing novel capsid variants with altered amino acid sequences. These parameter changes in the capsid structure enable improved tissue tropism and delivery efficiency while maintaining the overall AAV vector framework, thus resolving the contradiction between delivery efficiency and structural complexity.
Solution Approach 2:
The patent creates composite capsid structures by combining elements from different AAV serotypes or engineering chimeric capsid proteins. This composite approach allows the vector to acquire enhanced tissue specificity and transduction efficiency from multiple parental vectors while maintaining a manageable structural complexity through modular design.
2Reliability
If AAV vectors are engineered with novel capsid proteins to improve tissue targeting, then transduction efficiency increases, but manufacturing complexity increases
Solution Approach 1:
The patent employs parameter changes in capsid protein sequences to improve transduction efficiency. By making targeted amino acid substitutions or additions in the capsid coding region, the invention achieves enhanced tissue targeting without requiring complete redesign of the manufacturing process, thus balancing transduction efficiency with ease of manufacture.
Solution Approach 2:
The patent segments the capsid protein into variable and conserved regions, allowing modification of specific domains responsible for tissue tropism while preserving the essential structural and assembly functions. This segmentation enables improved transduction efficiency through targeted mutations without complicating the overall manufacturing process, as the modular approach allows for standardized production methods.
3Adaptability or versatility
If capsid library construction strategy is used to enhance delivery efficiency, then transduction efficiency in various tissues improves, but device complexity increases
Solution Approach 1:
The patent applies parameter changes to capsid proteins by creating focused libraries with specific amino acid variations at key positions known to influence tissue tropism. This approach enables the development of vectors with adapted tissue specificity while controlling library complexity by limiting variations to functionally critical regions rather than the entire capsid sequence.
Solution Approach 2:
The patent designs capsid libraries with modular variable regions that can be swapped or combined to target different tissues. This universal framework allows a single base capsid design to be adapted for multiple tissue targets through systematic variation of specific domains, thereby achieving broad tissue tropism without proportionally increasing overall device complexity.
Data Source
AI summary
Provided herein are recombinant AAV vectors, AAV viral vectors, and capsid proteins for improved gene therapy, and methods for their manufacture and use.